Insights

Non-invasive market Theraclion offers Sonovein, the only non-invasive varicose vein treatment powered by HIFU, presenting a clear value proposition for hospitals and clinics seeking scar-free, faster-recovery procedures to attract patients and reduce post-procedure care.

CE-marked potential The CE-marked platform suggests regulatory readiness for many European markets, enabling sales conversations focused on standardization, reimbursement planning, and adoption by vascular and cosmetic clinics seeking innovative offerings.

U.S. opportunities In the United States, Sonovein is investigational and not for sale, signaling a pipeline opportunity contingent on regulatory progress or partnerships with trial sites, which sales teams can monitor for near-term licensing or collaboration deals.

Growth-ready team With a focused team of technologists and clinicians and a revenue range of one to ten million, Theraclion appears nimble for direct sales and strategic partnerships with medical device distributors targeting specialty vascular and cosmetic practices.

Competitive positioning As a niche MedTech player in a market with larger players, Theraclion can leverage its unique non-invasive, incision-free approach to pursue clinics seeking alternative treatments to surgery, offering differentiation through reduced recovery time and potential cost savings.

Similar companies to Theraclion

Theraclion Tech Stack

Theraclion uses 8 technology products and services including LinkedIn Ads, Unpkg, WordPress, and more. Explore Theraclion's tech stack below.

Theraclion's Email Address Formats

Theraclion uses at least 2 email formats:
Theraclion Email FormatsExamplePercentage
First.Last@theraclion.comJohn.Doe@theraclion.com
98%
First.Middle@theraclion.comJohn.Michael@theraclion.com
2%

Frequently Asked Questions

What is Theraclion's stock symbol?

Minus sign iconPlus sign icon
Theraclion is a publicly traded company; the company's stock symbol is TCLIF.

What is Theraclion's official website and social media links?

Minus sign iconPlus sign icon
Theraclion's official website is theraclion.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Theraclion generate?

Minus sign iconPlus sign icon
As of October 2026, Theraclion's annual revenue is estimated to be $1M - $10M.

What is Theraclion's NAICS code?

Minus sign iconPlus sign icon
Theraclion's NAICS code is 3391 - Medical Equipment and Supplies Manufacturing.

How many employees does Theraclion have currently?

Minus sign iconPlus sign icon
As of October 2026, Theraclion has approximately 50 employees across 4 continents, including Europe, Africa and Asia. Key team members include Chief Executive Officer: M. D., Cbo - Vice President Sales, Marketing & Applications: T. L. N. and Chief Medical Officer/Vp Veins: M. N. Explore Theraclion's employee directory with LeadIQ.

What industry does Theraclion belong to?

Minus sign iconPlus sign icon
Theraclion operates in the Medical Equipment Manufacturing industry.

What technology does Theraclion use?

Minus sign iconPlus sign icon
Theraclion's tech stack includes LinkedIn Ads, Unpkg, WordPress, Shopify, Google Fonts API, Brevo, Office 365 and ISO 14971.

What is Theraclion's email format?

Minus sign iconPlus sign icon
Theraclion's email format typically follows the pattern of First.Last@theraclion.com. Find more Theraclion email formats with LeadIQ.

How much funding has Theraclion raised to date?

Minus sign iconPlus sign icon
As of October 2026, Theraclion has raised $14M in funding. The last funding round occurred on Mar 20, 2025 for $1.6M.

When was Theraclion founded?

Minus sign iconPlus sign icon
Theraclion was founded in 2004.
Theraclion logo

Theraclion

Medical Equipment ManufacturingÎle-de-France, France11-50 Employees

Theraclion is a French medical equipment manufacturer focused on non-invasive treatment for varicose veins. Its Sonovein platform uses high-intensity focused ultrasound to treat varicose veins without incisions or an operating room, enabling patients to resume daily activities quickly. The technology is CE-marked and targets the surgical replacement market for varicose vein procedures, though in the United States the device remains limited to investigational use. Based in Malakoff, near Paris, the company operates with a small team primarily engaged in technological and clinical development. Theraclion positions itself within the MedTech sector as a provider of non-surgical, room-free solutions for vascular treatment.

Section iconCompany Overview

Stock Symbol
TCLIF
NAICS Code
3391 - Medical Equipment and Supplies Manufacturing
Founded
2004
Employees
11-50

Section iconFunding & Financials

  • $14M

    Theraclion has raised a total of $14M of funding over 4 rounds. Their latest funding round was raised on Mar 20, 2025 in the amount of $1.6M as a Post IPO Debt.

  • $1M - $10M

    Theraclion's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.